Please assess the completion status of the following clinical trial:

Trial Title: Melatonin Treatment for Night-Eating Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 - 65 years of age~2. English speaking~3. Meet DSM-V (Diagnostic and Statistical Manual - version 5) criteria for Night Eating Syndrome (NES)~Exclusion Criteria:~1. Unable to provide informed consent~2. Presence of alcohol/substance dependence~3. Presence of other eating disorders such as Binge Eating Disorder, Anorexia Nervosa.~4. Significant uncontrolled systemic illness (e.g. chronic renal failure, chronic liver disease, poorly controlled diabetes, poorly controlled congestive heart failure, chronic infectious disease, chronic autoimmune disease)~5. Women who are pregnant or breastfeeding~6. Allergy or hypersensitivity to melatonin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Melatonin (Type: EXPERIMENTAL): A commercially available rapid-release formulation of melatonin (5 mg) capsules to be administered once a day for a total of 8 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo capsules to be administered once a day for a total of 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).